Online first
Review paper
Published online: 2024-06-10

open access

Page views 29
Article views/downloads 12
Get Citation

Connect on Social Media

Connect on Social Media

Subcutaneous methotrexate-containing medicinal products — comparative studies of pharmaceutical form and immediate packaging

Dorota Sikorska1, Włodzimierz Samborski1

Abstract

Despite the passage of time and the emergence of more drugs on the pharmaceutical market, methotrexate (MTX) is still considered the primary drug for the treatment of rheumatoid arthritis and other inflammatory rheumatic disorders. However, the best forms of MTX therapy are still being sought. Based on the available literature, subcutaneous MTX is preferred, especially when using higher doses, due to its better bioavailability and lower incidence of side effects. Nevertheless, some patients still prefer oral therapy. Therefore, it is important to make patients as comfortable as possible with injectable MTX, which can contribute to better cooperation. This paper presents the results from a comparative analysis of selected 15 mg pre-filled syringes (PFS) containing MTX available on the Polish market in terms of technological differences and product administration.

Article available in PDF format

View PDF (Polish) Download PDF file

References

  1. Malaviya AN. Landmark papers on the discovery of methotrexate for the treatment of rheumatoid arthritis and other systemic inflammatory rheumatic diseases: a fascinating story. Int J Rheum Dis. 2016; 19(9): 844–851.
  2. Hazlewood GS, Barnabe C, Tomlinson G, et al. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis. BMJ. 2016; 353: i1777.
  3. Kerschbaumer A, Sepriano A, Smolen JS, et al. 2016 update of the EULAR recommendations for the management of early arthritis. Ann Rheum Dis. 2017; 76(6): 948–959.
  4. Li D, Yang Z, Kang P, et al. Subcutaneous administration of methotrexate at high doses makes a better performance in the treatment of rheumatoid arthritis compared with oral administration of methotrexate: A systematic review and meta-analysis. Semin Arthritis Rheum. 2016; 45(6): 656–662.
  5. Schiff MH, Jaffe JS, Freundlich B. Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration. Ann Rheum Dis. 2014; 73(8): 1549–1551.
  6. Zhang X, Zhang Y, Ye X, et al. Overview of phase IV clinical trials for postmarket drug safety surveillance: a status report from the ClinicalTrials.gov registry. BMJ Open. 2016; 6(11): e010643.
  7. Cesana BM, Biganzoli EM. Phase IV Studies: Some Insights, Clarifications, and Issues. Curr Clin Pharmacol. 2018; 13(1): 14–20.